Needham & Company LLC Issues Pessimistic Forecast for Cooper Companies (NASDAQ:COO) Stock Price

Cooper Companies (NASDAQ:COO) had its price objective reduced by research analysts at Needham & Company LLC from $100.00 to $99.00 in a research report issued to clients and investors on Tuesday, MarketBeat reports. The firm presently has a “buy” rating on the medical device company’s stock. Needham & Company LLC’s price objective would suggest a potential upside of 22.75% from the stock’s current price.

COO has been the subject of a number of other research reports. JPMorgan Chase & Co. lifted their price target on shares of Cooper Companies from $66.00 to $78.00 and gave the stock a “neutral” rating in a research note on Friday, December 5th. Stifel Nicolaus set a $95.00 target price on shares of Cooper Companies and gave the company a “buy” rating in a research note on Friday, December 5th. Weiss Ratings upgraded Cooper Companies from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, January 12th. Barclays set a $98.00 price objective on Cooper Companies and gave the company an “overweight” rating in a report on Monday, January 26th. Finally, William Blair raised Cooper Companies to a “strong-buy” rating in a report on Friday. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $90.77.

Cooper Companies Stock Down 0.9%

Shares of NASDAQ COO opened at $80.65 on Tuesday. The company has a debt-to-equity ratio of 0.30, a quick ratio of 1.13 and a current ratio of 1.89. Cooper Companies has a 1 year low of $61.78 and a 1 year high of $97.21. The stock’s 50-day simple moving average is $81.16 and its 200-day simple moving average is $74.31. The firm has a market cap of $15.81 billion, a price-to-earnings ratio of 42.90, a PEG ratio of 2.32 and a beta of 1.03.

Cooper Companies (NASDAQ:COO) last issued its quarterly earnings data on Thursday, December 4th. The medical device company reported $1.15 earnings per share for the quarter, beating analysts’ consensus estimates of $1.11 by $0.04. Cooper Companies had a return on equity of 10.02% and a net margin of 9.16%.The firm had revenue of $1.07 billion during the quarter, compared to analyst estimates of $1.06 billion. During the same quarter last year, the firm earned $1.04 EPS. Cooper Companies’s quarterly revenue was up 4.6% on a year-over-year basis. Cooper Companies has set its FY 2026 guidance at 4.450-4.600 EPS and its Q1 2026 guidance at 1.020-1.040 EPS. As a group, equities analysts anticipate that Cooper Companies will post 3.98 earnings per share for the current fiscal year.

Insider Activity at Cooper Companies

In related news, Director Cynthia L. Lucchese acquired 1,784 shares of the stock in a transaction that occurred on Monday, December 22nd. The stock was purchased at an average cost of $84.06 per share, for a total transaction of $149,963.04. Following the purchase, the director directly owned 9,445 shares in the company, valued at $793,946.70. This represents a 23.29% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Holly R. Sheffield bought 1,230 shares of the company’s stock in a transaction on Tuesday, December 16th. The stock was bought at an average cost of $80.75 per share, for a total transaction of $99,322.50. Following the completion of the transaction, the insider directly owned 39,052 shares of the company’s stock, valued at $3,153,449. This trade represents a 3.25% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last three months, insiders purchased 16,014 shares of company stock valued at $1,304,416. 1.98% of the stock is owned by insiders.

Hedge Funds Weigh In On Cooper Companies

Institutional investors have recently modified their holdings of the company. Bell Investment Advisors Inc lifted its position in Cooper Companies by 106.3% in the 3rd quarter. Bell Investment Advisors Inc now owns 425 shares of the medical device company’s stock valued at $29,000 after purchasing an additional 219 shares during the last quarter. J.Safra Asset Management Corp increased its stake in shares of Cooper Companies by 204.8% in the second quarter. J.Safra Asset Management Corp now owns 506 shares of the medical device company’s stock valued at $36,000 after purchasing an additional 340 shares during the period. CYBER HORNET ETFs LLC acquired a new stake in shares of Cooper Companies in the second quarter valued at approximately $36,000. True Wealth Design LLC raised its holdings in shares of Cooper Companies by 484.8% during the fourth quarter. True Wealth Design LLC now owns 462 shares of the medical device company’s stock valued at $38,000 after buying an additional 383 shares during the last quarter. Finally, Cromwell Holdings LLC boosted its position in shares of Cooper Companies by 128.8% during the fourth quarter. Cromwell Holdings LLC now owns 485 shares of the medical device company’s stock worth $40,000 after buying an additional 273 shares during the period. Institutional investors own 24.39% of the company’s stock.

Cooper Companies Company Profile

Cooper Companies, Inc (NASDAQ: COO) is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women’s health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry.

The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories.